Welcome to our dedicated page for Therapeuticsmd SEC filings (Ticker: TXMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to know how much royalty cash TherapeuticsMD pulls in from ANNOVERA or IMVEXXY? Most investors start with the company’s 10-K and 10-Q, but locating those figures—and the underlying licensing terms—can take hours. Our dedicated page brings every TherapeuticsMD SEC filing into one place, from the TherapeuticsMD quarterly earnings report 10-Q filing to the latest TherapeuticsMD 8-K material events explained.
You’ll find each document the moment it hits EDGAR and, more importantly, an AI-powered summary that translates legalese into plain English. Whether you’re understanding TherapeuticsMD SEC documents with AI, scanning a TherapeuticsMD annual report 10-K simplified, or checking the TherapeuticsMD proxy statement executive compensation, Stock Titan highlights royalty revenue trends, milestone triggers, and pending patent expirations in seconds.
Need real-time alerts on management’s trades? Our system flags every TherapeuticsMD Form 4 insider transactions real-time, letting you track TherapeuticsMD insider trading Form 4 transactions and compare them to cash-flow shifts disclosed in the same quarter. Use built-in tools to overlay TherapeuticsMD earnings report filing analysis with TherapeuticsMD executive stock transactions Form 4 so you can see when buying or selling aligns with royalty milestones. From first-read AI briefs to full-text search across historical filings, we streamline the entire journey of analysing this women’s-health royalty specialist.
TherapeuticsMD has transformed into a pharmaceutical royalty company after the December 30, 2022 Mayne Transaction that generated $140.0 million in cash plus approximately $12.1 million for net working capital and $1.0 million in prepaid royalties. Under the Mayne License Agreement Mayne Pharma pays royalties of 8.0% on the first $80.0 million of U.S. annual net sales and 7.5% thereafter, with a $3.0 million minimum annual royalty for 12 years (adjusted 3% annually) and a 20-year royalty term.
For the quarter ended June 30, 2025 TherapeuticsMD reported $952 thousand of license revenue (up from $234 thousand a year earlier) and net income of $551 thousand or $0.05 per share. Cash totaled $6.069 million and royalty receivables were $3.743 million (short-term) and $14.840 million (long-term). The company discloses concentration (100% of license revenue from Mayne, Theramex and Knight), ongoing disputes with Mayne Pharma over net working capital and indemnification that gave rise to litigation, and states substantial doubt about its ability to continue as a going concern for the next twelve months.
TherapeuticsMD, Inc. disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02 via Item 7.01. The filing makes clear the material in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and includes an explicit disclaimer that the company has no obligation to publicly update any forward-looking statements. The report lists the press release and an Inline XBRL cover page as exhibits.
FAQ
What is the current stock price of Therapeuticsmd (TXMD)?
What is the market cap of Therapeuticsmd (TXMD)?
